Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling

Osimertinib, a 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line standard-of-care for EGFR-mutant non-small cell lung cancer (NSCLC) patients, while acquired drug resistance will inevitably occur. Interleukin-6 (IL-6) is a keystone cytokine in in...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Li, Zhujun, Lu, Conghua, Li, Jianghua, Zhang, Kejun, Lin, Caiyu, Tang, Xiaolin, Liu, Zhulin, Zhang, Yimin, Han, Rui, Wang, Yubo, Feng, Mingxia, Zhuang, Yuan, Hu, Chen, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866396/
https://www.ncbi.nlm.nih.gov/pubmed/35197546
http://dx.doi.org/10.1038/s42003-022-03111-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866396/
https://www.ncbi.nlm.nih.gov/pubmed/35197546
http://dx.doi.org/10.1038/s42003-022-03111-7

Ejemplares similares